Deep Blue Medical Advances, Inc. | $5,600,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)
Ideally | $10,000,000 | (Apr 22, 2026)
Waiv, formerly Owkin Dx
France
- Paris
- 13/03/2026
- Unknown
- $33,000,000
Waiv has evolved to meet this moment:
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
- Industry Biotechnology Research
- Website https://wearewaiv.com/
- LinkedIn https://www.linkedin.com/company/we-are-waiv/
Monk | $25,000,000 | (Apr 22, 2026)
Reliable Robotics Corporation | $160,000,000 | (Apr 22, 2026)
Humble Robotics | $24,000,000 | (Apr 22, 2026)
Sinai.ai | $1,450,000 | (Apr 22, 2026)
Qualitate | $7,000,000 | (Apr 22, 2026)
Exergy3 Limited | $13,523,900 | (Apr 22, 2026)
Syenta | $26,000,000 | (Apr 22, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)